Discover Camcevi. Zero Cancer Run/Walk, June 10, 2023, Mokeno, IL
site-logo
AVAILABLE
TO ORDER
 

This site is intended for use by U.S. residents only.

©2023 CAMCEVI. All rights reserved. WS-CAM-2200004 V7

RESOURCES & SUPPORT

Formulary Coverage Update

CAMCEVI® has coverage in more than 96% of the Medicare medical benefits lives in the United States and more than 92% of the commercial medical benefits lives in the United States. Contacting the patient’s health plan or submitting a benefits verification is encouraged as actual coverage could vary based on the member’s benefit design.

Formulary Coverage Finder

The formulary coverage tool below can help check CAMCEVI coverage for various plans. Coverage varies by type and plan.

Formulary Coverage Tool

THE ACCORDCARES™ CO-PAY AND PATIENT ASSISTANCE PROGRAMS

AccordCares offers key support and resources to your patients who may require financial assistance with their treatment.

Eligible patients may pay as little as:
$0 Co-Pay
per Camcevi treatment
Learn more

Learn More About CAMCEVI

CAMCEVI Syringe

Learn More About CAMCEVI

Frequently asked questions
Accord Cares

PATIENT SUPPORT

Patients who meet eligibility criteria may be eligible for payment assistance.

Get support Download Enrollment FormDownload Enrollment Form

Unique J Code with
pass-through status

CAMCEVI received pass-through status effective October 1, 2022*.

Payment instructions now available in Oct. 2022 OPPS update.

Download BillingDownload billing &
reimbursement guide

*CMS Status Indicator = G (Pass-through Drugs and Biologicals)

    ×

    *CMS Status Indicator = G (Pass-through Drugs and Biologicals)

    DOWNLOAD THE ACCORDCONNECTS™ APP

    Manage and track your CAMCEVI® inventory.

    Download now
    Accord-Connects-iphone

    SIMPLE ORDERING

    Accord BioPharma is actively working to expand our network of distribution partners and GPOs for you.

    Distribution Partners

    Name
    Amerisource SD
    Telephone
    800.543.2111
    Order Link
    Besse Online
    Name
    Besse Medical
    Telephone
    800.543.2111
    Order Link
    Besse Online
    Name
    Cardinal SD
    Telephone
    855.855.0708
    Order Link
    Specialty Online
    Name
    McKesson MSCD Oncology Multispecialty
    Telephone
    800.482.6700
    855.477.9800
    Order Link
    MSCD Online
    Name
    McKesson MPB
    Telephone
    877.625.2566
    Order Link
    McKesson Connect

    GPO Partners

    Name
    UROGPO
    Telephone
    404.250.3568
    Order Link
    Order Online
    Name
    International Urology Network (IUN)
    Telephone
    800.543.2111
    Name
    VitalSource™ GPO
    Telephone
    877.453.3972
    Order Link
    Specialty Online
    Unity and OnMark GPOs: Information for Oncology Network and specialty practice groups can be found on McKesson’s Customer Portal.

    HAVE A QUESTION?

    Let us simplify it for you.

    CONNECT WITH A REPRESENTATIVE

      GET UPDATES

      Stay informed about
      CAMCEVI with regular updates,
      education, and more.

      *Required fields

      IMPORTANT SAFETY INFORMATION

      Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

      CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

      Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

      Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

      Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

      Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

      Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

      Monitor serum levels of testosterone following injection of CAMCEVI.

      Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

      The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

      INDICATION

      CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

      Click here for full Prescribing Information.

      Reference:

      1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.